Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MIKHAIL I SHTIVELBAND

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1740254473
CMS profile
169412
Location
CHANDLER, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$3,444.92

192 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MIKHAIL I SHTIVELBAND

NPI 1740254473 · CMS profile ID 169412

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CHANDLER, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740254473?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MIKHAIL I SHTIVELBAND, NPI 1740254473, CMS profile ID 169412. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740254473?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MIKHAIL I SHTIVELBAND, NPI 1740254473, CMS profile ID 169412. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740254473?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MIKHAIL I SHTIVELBAND, NPI 1740254473, CMS profile ID 169412, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1740254473?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

192 matching records · $3,444.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 192 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 192.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $6.2708/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885500281 CMS
Seagen Inc. $18.3708/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904086701 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.7108/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929807229 CMS
Celgene Corporation $5.4207/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492645 CMS
Amgen Inc. $13.4807/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939838357 CMS
E.R. Squibb & Sons, L.L.C. $9.6107/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492771 CMS
Novartis Pharmaceuticals Corporation $15.0407/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894371168 CMS
Janssen Biotech, Inc. $6.7207/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885500297 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.6407/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955826407 CMS
PFIZER INC. $14.9007/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949201611 CMS
AstraZeneca Pharmaceuticals LP $23.4407/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914769447 CMS
PFIZER INC. $20.4607/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949178657 CMS
GENZYME CORPORATION $17.0107/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938904207 CMS
AstraZeneca Pharmaceuticals LP $18.3507/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915731923 CMS
E.R. Squibb & Sons, L.L.C. $13.3607/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492635 CMS
Merck Sharp & Dohme LLC $15.5006/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944491989 CMS
Amgen Inc. $12.6406/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939838355 CMS
Celgene Corporation $5.3906/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492631 CMS
EMD Serono, Inc. $18.2306/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941530595 CMS
AstraZeneca Pharmaceuticals LP $14.7506/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914796895 CMS
E.R. Squibb & Sons, L.L.C. $9.7006/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492629 CMS
G1 Therapeutics, Inc. $18.2606/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954038669 CMS
Janssen Biotech, Inc. $3.9306/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885500253 CMS
Amgen Inc. $14.9006/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939838349 CMS
ARRAY BIOPHARMA INC $13.5706/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949178707 CMS
E.R. Squibb & Sons, L.L.C. $11.5206/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492637 CMS
E.R. Squibb & Sons, L.L.C. $2.7206/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492639 CMS
Janssen Biotech, Inc. $19.2706/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885500285 CMS
Bayer HealthCare Pharmaceuticals Inc. $26.8306/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929809777 CMS
E.R. Squibb & Sons, L.L.C. $9.9406/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492613 CMS
Amgen Inc. $12.7606/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939838341 CMS
ABBVIE INC. $12.8706/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891596773 CMS
GlaxoSmithKline, LLC. $20.8306/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944563875 CMS
Celgene Corporation $16.5806/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492605 CMS
Merck Sharp & Dohme LLC $15.6505/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944486857 CMS
E.R. Squibb & Sons, L.L.C. $12.6805/26/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492601 CMS
Janssen Biotech, Inc. $18.4005/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885500239 CMS
Bayer HealthCare Pharmaceuticals Inc. $12.4305/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930622727 CMS
JAZZ PHARMACEUTICALS INC. $22.4705/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951357427 CMS
ABBVIE INC. $20.9105/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891596771 CMS
Janssen Biotech, Inc. $10.9905/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885500323 CMS
GENZYME CORPORATION $18.7405/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938904187 CMS
Celgene Corporation $4.4105/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492595 CMS
Celgene Corporation $16.8205/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492597 CMS
Merck Sharp & Dohme LLC $21.8605/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944489173 CMS
Genentech USA, Inc. $22.6405/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950780097 CMS
PFIZER INC. $14.3305/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949102777 CMS
GENZYME CORPORATION $18.3305/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938904189 CMS
Pharmacyclics LLC, an AbbVie Company $16.3605/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890347819 CMS
Genentech USA, Inc. $26.5205/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950782129 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $26,137.87 162
PY2020 $5,395.00 98
PY2021 $2,612.82 171
PY2022 $3,444.92 192
PY2023 $1,960.79 101
PY2024 $1,064.56 57
PY2025 $922.34 39

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $906,720.78 6
PY2024 Principal investigator $693,194.87 10
PY2023 Recipient $1,237.95 1
PY2023 Principal investigator $1,089,983.71 35
PY2022 Recipient $1,146.00 1
PY2022 Principal investigator $1,254,442.06 43
PY2021 Recipient $949.05 1
PY2021 Principal investigator $1,873,783.44 55
PY2020 Recipient $2,884.09 1
PY2020 Principal investigator $1,486,812.85 103
PY2019 Principal investigator $1,797,311.17 110

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

6 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $3,588.01 04/24/2025 Non-covered Recipient Entity
IRONWOOD CANCER AND RESEARCH CENTER CHANDLER I
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1185541724
Principal investigator 1 Novartis Pharmaceuticals Corporation $22.96 03/26/2025 Non-covered Recipient Entity
IRONWOOD CANCER AND RESEARCH CENTER CHANDLER I
Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria No dispute reported 06/30/2026 1190308578
Principal investigator 1 Eli Lilly and Company $22,042.00 02/10/2025 Non-covered Recipient Entity
IRONWOOD CANCER AND RESEARCH CENTERS
EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY No dispute reported 06/30/2026 1187885190
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,350.00 02/04/2025 Non-covered Recipient Entity
Ironwood Cancer & Researc
A Phase III, Open-Label, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy followed by Rituximab in Subjects with Previously Untreated Follicular Lymphoma No dispute reported 06/30/2026 1235996527
Principal investigator 1 AstraZeneca Pharmaceuticals LP $294,777.11 01/15/2025 Non-covered Recipient Entity
IRONWOOD CANCER AND RESEARCH CENTER CHANDLER I
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) No dispute reported 06/30/2026 1185541722
Principal investigator 1 Novartis Pharmaceuticals Corporation $583,940.70 01/02/2025 Non-covered Recipient Entity
IRONWOOD CANCER AND RESEARCH CENTER CHANDLER I
A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study No dispute reported 06/30/2026 1190308576